Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.
TNGX
Tango Therapeutics, Inc. · NASDAQ
Sign up free to see this.
Mkt Cap
$3.9B
Volume
15.3M
52W High
$34.39
52W Low
$6.69
PE Ratio
—
Avg Vol
4.1M
As of 10/23/26
Div Yield
—
Beta
1.38
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about TNGX?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $TNGX · 0 threads
Sign in to post on $TNGX
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.